Actinium Pharmaceuticals has announced that it has named Jennifer Liberi Director of Clinical Operations. Read More »

Recent research conducted by ResearchersAgainstAlzheimer’s (RA2), an UsAgainstAlzheimer’s (UsA2) network, reports 17 new drugs aimed at treating Alzheimer’s will be developed in the next five years. Read More »

Eisai Co. Ltd. and Ajinomoto Co. Inc. have announced the establishment of EA Pharma Co. Ltd., based on the integration agreement signed by both companies on October 15 of last year. Read More »

Eisai Co. Ltd. has announced that Eisai Inc., the company’s subsidiary located in the United States, has entered into a shared purchase agreement that will transfer all of Eisai Inc.’s shares of AkaRx Inc. to PBM Capital Group LLC. Read More »

Pfizer and Bristol-Myers Squibb have released the 17 abstracts that the two companies will present at the American College of Cardiology’s 65th Annual Scientific Session (ACC.16) in Chicago on April 2-4. Read More »

Sanofi and Regeneron Pharmaceuticals will be presenting new joint Phase 3 data from the clinical trial for the Praluent (alirocumab) Injection at the American College of Cardiology’s 65th Annual Scientific Session & Expo (ACC.16) in Chicago on April 2-4. Read More »

Teva Pharmaceutical Industries has announced that the U.S. Food and Drug Administration (FDA) has approved its interleukin 5 antagonist monoclonal antibody (lgG4 kappa), CINQAIR (reslizumab) Injection. Read More »

UnitedHealthcare celebrated the opening of its new office in Davenport, Iowa last week and the expansion of its headquarters located in West Des Moines. Read More »

Walgreens has confirmed that it will be returning as the second annual Red Nose Day’s exclusive retail partner on May 26. Read More »

UnitedHealthcare Community Plan of Louisiana announced this week that it has awarded more than $3.4 million to 249 physician practices across the state as bonus payments for improving the quality of care for patients who are enrolled in UnitedHealthcare’s Medicaid plans. Read More »

The CVS Health Foundation has released new data from programs that were part of a collaborative effort with the National Association of Free & Charitable Clinics (NAFC) and the National Association of Community Health Centers (NACHC) as part of CVS Health’s multi-year, $5-million commitment to increase nationwide access to health care in communities. Read More »

The Japanese Ministry of Health, Labor and Welfare (MHLW) today approved AstraZeneca's Tagrisso (osimertinib, AZD9291). Read More »

CVS Health has announced that CVS Caremark, its pharmacy benefits manager, has been awarded the Mail Service Pharmacy accreditation by the URAC, a health care accreditation organization located in Washington, D.C. Read More »

Alkermes plc has released data from its schizophrenia portfolio that will be featured at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference that will be held from April 2-6 in Florence Italy. Read More »

Sarepta Therapeutics has announced that its New Drug application (NDA) for eteplirsen will be reviewed by the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System (PCNS) Drug Advisory Committee on April 25. Read More »

Cigna has announced that Cigna Hospital Care, the company’s new group hospital indemnity insurance policy, will be available starting in April. Read More »

Allergan has announced that it has submitted an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for the approval of market Paclitaxel Protein-Bound Particles for Injectable Suspension, 100 mg/vial. Read More »

Meritain Health, an Aetna subsidiary, has announced a collaboration with Banner Health Network (BHN) and Aetna Whole Health, which provides members with access to coordinated care administered by physicians and facilities in accountable care networks nationwide. Read More »

Surescripts has provided new data showing that more than 48,000 providers in New York have turned to technology to help fight prescription fraud and abuse. Read More »

Biota Pharmaceuticals has announced the completed sale of its assets relating to its broad spectrum antibiotic program to a new subsidiary of Spero Therapeutics LLC. Read More »